(-0.02%) 5 477.50 points
(-0.02%) 38 810 points
(0.01%) 19 924 points
(0.26%) $80.54
(1.11%) $2.82
(0.11%) $2 331.50
(-0.45%) $29.26
(-0.13%) $969.60
(0.02%) $0.932
(-0.12%) $10.64
(0.07%) $0.788
(-1.86%) $86.81
Live Chart Being Loaded With Signals
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States...
Stats | |
---|---|
Šios dienos apimtis | 639 899 |
Vidutinė apimtis | 1.25M |
Rinkos kapitalizacija | 577.47M |
EPS | $-0.100 ( Q1 | 2024-05-02 ) |
Kita pelno data | ( $-0.100 ) 2024-08-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-6.95 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00400 (0.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-23 | Burgess Daniel D | Buy | 67 000 | Stock Option (Right to Buy) |
2024-05-23 | Manchester Keith S | Buy | 67 000 | Stock Option (Right to Buy) |
2024-05-23 | Henriques Richard C Jr | Buy | 67 000 | Stock Option (Right to Buy) |
2024-05-23 | Meyers James R | Buy | 67 000 | Stock Option (Right to Buy) |
2024-05-23 | Rewolinski Melissa | Buy | 67 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
91.24 |
Last 96 transactions |
Buy: 35 936 262 | Sell: 1 766 657 |
Tūris Koreliacija
Arbutus Biopharma Corp Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
AGBAW | 0.914 |
MTTR | 0.914 |
DECAU | 0.894 |
IBTA | 0.884 |
ANL | 0.863 |
NNAVW | 0.851 |
ICCH | 0.851 |
CALC | 0.848 |
DHAI | 0.844 |
MOBX | 0.832 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
OZEM | -1 |
BKHA | -0.909 |
OCTO | -0.903 |
HTZWW | -0.894 |
INTJ | -0.881 |
QRMI | -0.88 |
SCLX | -0.876 |
CDIO | -0.87 |
CTCX | -0.856 |
SERV | -0.853 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Arbutus Biopharma Corp Koreliacija - Valiuta/Žaliavos
Arbutus Biopharma Corp Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $18.14M |
Bruto pelnas: | $16.74M (92.26 %) |
EPS: | $-0.440 |
FY | 2023 |
Pajamos: | $18.14M |
Bruto pelnas: | $16.74M (92.26 %) |
EPS: | $-0.440 |
FY | 2022 |
Pajamos: | $39.02M |
Bruto pelnas: | $37.59M (96.34 %) |
EPS: | $-0.460 |
FY | 2021 |
Pajamos: | $10.99M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-0.830 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.